This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results

Impact · against what's priced in

Celcuity's recent 669% price surge suggests the market has already aggressively priced in its clinical progress and the NDA submission for gedatolisib. While the concentrated bet by Apis Capital provides a positive signal of institutional conviction, it is a lagging indicator that confirms the existing trend rather than introducing a new catalyst.

CELC+0.30: No priced-in read yet

This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results

What matters in this story

Sol-Gel Eyes 2028 Launch as SGT-610 Nears Pivotal Gorlin Syndrome Data

This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results

What matters in this story

Sol-Gel Eyes 2028 Launch as SGT-610 Nears Pivotal Gorlin Syndrome Data

How each ticker is affected

Connected tickers

Track these names every morning.

Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?

This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results

What matters in this story

Next reads from the same story arc

Sol-Gel Eyes 2028 Launch as SGT-610 Nears Pivotal Gorlin Syndrome Data

This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results

What matters in this story

Next reads from the same story arc

Sol-Gel Eyes 2028 Launch as SGT-610 Nears Pivotal Gorlin Syndrome Data

How each ticker is affected

Connected tickers

Track these names every morning.

Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?